Enhancing Prospective Thinking in Early Recovery (PARK)

Completed · Early Phase 1 · Has a placebo group

Conditions studied: Opioid Use, Opioid Use Disorder, Substance Use Disorders

In brief

The goal of this clinical trial is to demonstrate the commercial potential for a novel virtual reality (VR) intervention in preparation for Phase II development. This clinical trial will test the VR intervention for efficacy in reducing opioid use, increasing abstinence, and other self-reported and behavioral focus on future outcomes in individuals in early recovery from opioid use disorder. * Will the VR group, compared to the control group, have a lower number of opioid use days? * Will the VR group, compared to the control group, have longer periods of abstinence at the 30-day follow-up? * Will the VR group, compared to the control group, have significantly increased opioid abstinence rates? * Will the VR group, compared to baseline and the control group, show increased future self-identification post-VR intervention? * Will the VR group, compared to baseline and the control group, show increased future orientation post-VR intervention? * Will the VR group, compared to baseline and the control group, show an increased preference for delayed rewards in a laboratory delay discounting task post-VR intervention? * Will the VR group, compared to baseline and the control group, exceed in behavioral effects (i.e., future self-identification, future orientation, and increased preference for delayed rewards) at the 30-day follow-up? Researchers will compare the VR test group and the control group to see if there are differences in the results for the questions outlined above.

Key facts

Study ID

NCT05908097

Run by

Indiana University

People needed

104

Starts

2023-04-04

Expected to finish

2025-09-14

Last updated by the study team

2026-01-13

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Abstinence between ≥14 days and ≤ 1 year
• 18-60 years old
• Verbal endorsement of commitment to recovery
• Outpatient
• Psychotropic drugs for SUD-comorbidity
• Mu-Opioid drugs
• Drug/alcohol abstinence ≥ 24 hours at the time of the study day visit
• English comprehension

You may not qualify if…

• Unstable medical disorders
• Outside the age range of 18-60
• Habitual drug use
• Smell/taste disorders
• Unstable psychiatric conditions
• Extravagant/elaborate face tattoos

Where it is running

• Indiana University School of Medicine - Goodman Hall — Indianapolis, Indiana, United States
• IUSM - Goodman Hall — Indianapolis, Indiana, United States
• Serenity Lane Alcohol & Drug Treatment — Coburg, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.